Director at Armata (NASDAQ: ARMP) receives 25,640 stock options grant

Rhea-AI Filing Summary

Armata Pharmaceuticals director Robin Kramer received a grant of stock options, giving the right to buy 25,640 shares of common stock at an exercise price of $11.61 per share. These options vest in full on March 9, 2027, subject to continuous service, and expire on March 9, 2036. Following this grant, Kramer holds 25,640 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kramer Robin

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$11.61	03/09/2026		A		25,640		(1)	03/09/2036	Common Stock	25,640	$0.00	25,640	D

Explanation of Responses:

1. The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

	/s/ Robin Kramer	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Armata Pharmaceuticals (ARMP) report for Robin Kramer?

Armata Pharmaceuticals reported that director Robin Kramer received a grant of 25,640 stock options. The options give the right to buy common stock at an exercise price of $11.61 per share, with vesting and expiration terms set in the award.

What are the key terms of Robin Kramer’s 25,640 Armata (ARMP) stock options?

Robin Kramer’s 25,640 stock options have an exercise price of $11.61 per share and expire on March 9, 2036. The options will vest in full on March 9, 2027, provided Kramer remains in continuous service through that vesting date.

When do Robin Kramer’s Armata Pharmaceuticals (ARMP) stock options vest?

Robin Kramer’s stock options vest in full on March 9, 2027. Vesting is conditional on continuous service with Armata Pharmaceuticals through that date, meaning the options become fully exercisable only after meeting this service requirement.

What is the exercise price and expiration date of the new ARMP stock options?

The granted stock options have an exercise price of $11.61 per share and an expiration date of March 9, 2036. This provides a long-dated right to purchase Armata Pharmaceuticals common stock if the vesting and other conditions are satisfied.

How many Armata (ARMP) stock options does Robin Kramer hold after this grant?

After this grant, Robin Kramer holds 25,640 stock options directly. These options correspond to 25,640 underlying shares of Armata Pharmaceuticals common stock, all subject to the same exercise price, vesting schedule, and expiration date described in the award.